Bupivacaine liposome (Exparel)
Small molecule
Also known as SKY0402
Evidence outlook
Approved: Acute Pain
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00890682 NCT00890682 · Acute Pain Registry: NCT00890682 | 3 | Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores (0-24 hours) 2009-11 | Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores (0-24 hours): SKY0402 124 Units on a scale*hours (Standard Error 4.5) | Placebo 146 Units on a scale*hours (Standard Error 4.6) | not yet graded | link ↗ |
View 1 more trial
NCT00890721 NCT00890721 · Acute Pain Registry: NCT00890721 | 3 | The Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo. 2009-11 | The Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo. (72 hours): SKY0402 141.8 units on a scale*hr (Standard Error 10.7) | Placebo 202.5 units on a scale*hr (Standard Error 10.7) | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
This drug's own stage for Acute Pain: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Bupivacaine Liposome (Exparel): this drug | Approved | Small molecule | Amide Local Anesthetic | not yet graded | No reviewed efficacy summary in this indication | |
| Suzetrigine (Journavx) | Approved | Small molecule | Voltage-gated sodium channel NaV1.8 | Reliable signal | NCT05553366: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.6 units on a scale (Standard Error 6.3) | Suzetrigine (SUZ) 99.9 units on a scale (Standard Error 4.5) NCT05558410: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.1 units on a scale (Standard Error 6.1) | Suzetrigine (SUZ) 118.4 units on a scale (Standard Error 4.3) | |
| HRS-2129 | Phase 1(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Bupivacaine liposome (Exparel) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.